Acromegaly Treatment Market to Reach USD 2.51 Billion by 2030 driven by Expanded Oral Therapies and Rising Diagnosis Rates
"Acromegaly Treatment Market"
Mordor Intelligence has published a new report on the acromegaly treatment market offering a comprehensive analysis of trends, growth drivers, and future projections.
Introduction
According to a 2025 report on Acromegaly Treatment Market by Mordor Intelligence the market is projected to grow from USD 1.75 billion in 2025 to USD 2.51 billion by 2030, at a compound annual growth rate (CAGR) of 7.4%. Acromegaly is a rare hormonal disorder caused by excessive secretion of growth hormone (GH), typically due to a benign tumor on the pituitary gland. The condition leads to abnormal growth of bones and tissues, often resulting in physical deformities, metabolic complications, and cardiovascular issues if left untreated. The acromegaly treatment market has been growing steadily as awareness increases, diagnostic capabilities improve, and newer therapeutic approaches emerge.
Key Trends
The acromegaly treatment market is witnessing several notable trends shaping its trajectory:
• Shift toward long-acting and oral formulations Manufacturers are introducing extended-release depot injections and novel oral therapies. The FDA's 2020 approval of MYCAPSSA (oral octreotide) has opened doors for at home administration. Growth hormone receptor antagonists like pegvisomant and emerging oral agents (e.g. paltusotine) are attracting attention due to simplified regimens and improved patient adherence.
• Improved diagnosis and earlier detection protocols Updated guidelines and enhanced disease awareness globally are enabling earlier identification of GH secreting pituitary adenomas. This leads to timely treatment and is expected to boost market growth by approximately 1.9% CAGR in North America and Europe.
• Geographic growth acceleration in Asia-Pacific Asia-Pacific is projected to grow at an 8.2% CAGR through 2030, outpacing regional averages. Increased healthcare investments, growing specialist density, and expanding private insurance coverage especially in China, Japan, and South Korea are key growth drivers.
Market Segmentation
The acromegaly treatment market is segmented by product type and distribution channel:
By Product Type
Somatostatin analogs: Represent the largest segment in 2024 with a 55% market share. These are widely endorsed as first line therapy due to their strong efficacy. Depot formulations (e.g., lanreotide, octreotide) are well established, and clinical use continues to expand.
Growth hormone receptor antagonists (GHRAs): Although their market share is smaller currently, this segment is growing faster, projected at roughly 9.5% CAGR to 2030. Products like pegvisomant and oral agents such as paltusotine show strong biochemical control in trials.
Dopamine agonists: Utilize a different mechanism and typically serve as adjunct therapy or in mild acromegaly cases. This segment remains niche.
Other product types: Includes emerging therapies such as antisense RNA, GHRH receptor blockers, and novel injectables. These are mostly in early pipeline stages and target refractory cases.
By Distribution Channel
Hospital pharmacies: Captured approximately 61% of the market in 2024, largely due to the need for specialist oversight during initiation, dose titration, and imaging follow up of injectable therapies.
Retail pharmacies: Although smaller, this traditional outpatient channel remains important especially for refill prescriptions after stabilization under clinical supervision.
Online pharmacies: The fastest growing segment with an estimated CAGR of 13.6% through 2030. Growth is driven by the rise of oral treatments (e.g., MYCAPSSA) and broader telemedicine and digital dispensing adoption.
By Geography
North America: Largest regional market with 43% share in 2024. Dominance is supported by high diagnosis rates, new treatment approvals, and payer support (e.g., Medicare Part D cap)
Europe: A significant market with stable growth, supported by predictable EMA approval processes and health technology assessments.
Asia‑Pacific: Fastest growing region at around 8.2% CAGR. Growth is fueled by rising specialist availability and public/private insurance expansions in countries like China, India, Japan, and South Korea.
Middle East & Africa: Emerging market with limited current data but increasing interest in rare disease treatment access.
South America: Gradual development, with pockets of access in Brazil and Argentina driven by improved regulatory frameworks.
Key Players
The global acromegaly treatment market shows a moderately concentrated competitive landscape, led by both big pharmaceutical companies and innovative biotechs.
Novartis A leading global pharmaceutical company, Novartis stands out in this market thanks to its established portfolio of somatostatin analogs. The report highlights Novartis among the top five companies, reflecting its significant influence and market share in acromegaly treatment.
Ipsen Another major specialist in endocrine disorders, Ipsen's Somatuline (lanreotide) program is a consistently high revenue performer. The firm is frequently recognized alongside Novartis and Pfizer as a top acromegaly treatment provider.
Pfizer Pfizer is repeatedly listed among the top tier players in acromegaly treatment, indicating its meaningful presence likely via advanced depot therapies and a global distribution network.
Recordati S.p.A. Positioned within the core competitive ensemble, Recordati is noted for its focus on rare endocrine diseases and strategic acquisitions in the field, reinforcing its role in the acromegaly treatment space.
Amryt Pharma plc Identified as one of the major players, Amryt contributes to the market through innovative therapies and participation in developing newer treatment modalities for acromegaly
Conclusion
The acromegaly treatment market is on a healthy upward path, largely fueled by therapeutic innovations and improved diagnosis. Transition to long-acting depots and oral therapies offers convenience and enhanced adherence, while robust pipelines in GH receptor antagonists signal sustained growth.
Geographically, North America with a 43% market share in 2024 continues to dominate, underpinned by policy measures like the U.S. Medicare Part D cap and proactive health technology assessments. Meanwhile, Asia Pacific is emerging as the fastest growing region, presenting new market opportunities.
Looking forward, early diagnosis, increasing access through digital pharmacies, and expanding oral treatment options suggest continued market expansion. With a projected valuation of USD 2.51 billion by 2030 and a steady 7.4% CAGR, the acromegaly treatment landscape will continue to evolve rooted in patient centric delivery modes and clinical advancements.
For More Insights: https://www.mordorintelligence.com/industry-reports/acromegaly-treatment-market?utm_source=abnewswire
Industry Related Reports:
Somatostatin Analogs Market: The Somatostatin Analogs Market Report is segmented by Type (Octreotide, Lanreotide, Pasireotide, and Other Types), by Application (Acromegaly, Neuroendocrine Tumors (NETs), and Other Applications), and by Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market size and forecasts are provided in terms of value (USD) for all the above segments.
Neuroendocrine Tumor Treatment Market : The Neuroendocrine Tumor Treatment Market Report is segmented by Products (Somatostatin Analogs (SSAs), Targeted Therapy, Chemotherapy, and Others), by Indication (Lungs, Pancreas, Gastrointestinal, and Others), by End User (Hospitals, Clinics, and Others), and by Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report provides five years of historical data along with five years' market forecasts.
Get More Insights: https://www.mordorintelligence.com/industry-reports/neuroendocrine-tumor-treatment-market?utm_source=abnewswire
Norway Pharmaceutical Market: The Norway Pharmaceutical Market Report is segmented by ATC/Therapeutic Class (Cardiovascular System, Dermatologicals, Genito Urinary System, Anti-infective for Systemic Use, Antineoplastic and Immunomodulating Agents, Musculoskeletal System, Nervous System, Respiratory System, and Others), by Drug Type (Branded and Generic), and by Prescription Type (Prescription Drugs (Rx) and Over the Counter (OTC) Drugs).
About Mordor Intelligence: Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals. With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.
For any inquiries or to access the full report, please contact: media@mordorintelligence.com https://www.mordorintelligence.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
14 minutes ago
- Globe and Mail
3 Monster Growth Stocks to Buy in the Second Half of 2025
The second half of 2025 offers a chance for investors to shake off the cobwebs of tariffs and recession fears and focus on where the market is going, rather than where it has been. Archer Aviation (NYSE: ACHR) has been on a roller coaster, while Cognex (NASDAQ: CGNX) and First Solar (NASDAQ: FSLR) have sold off considerably year to date. Despite these jarring moves, these three companies could be worth buying in the second half of 2025 and holding for years to come. Read on to find out why. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Archer Aviation stock has soared since this time last year -- and it's poised to keep ascending. Scott Levine (Archer Aviation): If you take a look at Archer Aviation stock's performance in 2025, you'll see it has logged a modest 3% gain (as of June 20). If you expand your perspective to the past year, however, you'll find a much different story -- a 222% gain. In light of this, growth investors may feel like it's too late to hitch a ride with the electric vertical takeoff and landing (eVTOL) stock, but there's no reason to think that Archer can't gain considerably more altitude. Developing innovative aircraft -- such as Archer's eVTOL aircraft dubbed Midnight -- is no small feat. To ensure that the aircraft is safe, Archer is undergoing a rigorous certification process from the Federal Aviation Administration (FAA) that's nearing its conclusion. The company has received a variety of requisite certifications from the FAA and is currently working toward receiving Part 142, the final certificate it needs before commencing commercial operations. Management is optimistic about receiving the certification soon and projects it will start commercial operations in 2025. Separate from the FAA certification, Archer continues to make progress in securing partnerships. Most recently, it announced an agreement (valued at up to $18 million) to deploy its Midnight aircraft in Indonesia, which is the third agreement of its type. Archer has also inked agreements in the United Arab Emirates and Ethiopia. According to Business Research Insights, the eVTOL market is poised for significant growth. Whereas it was valued at about $1.2 billion in 2024, it's expected to climb to $20.1 billion by 2033. For those scanning the skies for a growth stock with tremendous upside, Archer hits the mark. Machine vision is the future of automated manufacturing Lee Samaha (Cognex): If you looked at a three-year chart of revenue growth -- or rather decline, in this case, as Cognex's revenue is down 15.3% over the period on a 12-month rolling basis -- the last thing you'd conclude is that it's a "monster growth" stock. That said, the chart below provides a broader perspective. CGNX Revenue (TTM) data by YCharts. Unfortunately, the last few years have been challenging, with high interest rates pressuring end demand in two key markets -- automotive and consumer electronics. Meanwhile, the company's logistics end market (primarily e-commerce warehousing) experienced a boom during the lockdowns, only to face a correction in the following years. Still, Cognex's long-term growth trend remains impressive, and management highlighted the opportunity ahead during its recent investor day event. In a nutshell, management expects a combination of underlying industry growth of 4%, with 6% to 7% growth on top of that from the increasing penetration of machine vision into automated processes. Throw in 3% growth from inorganic sources (Cognex is the industry leader, so acquisitions are likely), and it results in long-term growth of 13% to 14% per annum. Those assumptions appear reasonable, considering the ever-increasing complexity of production, the need to improve manufacturing efficiency and quality control, the desire to reshore production to higher-labor-cost countries, and the increased value added to its solutions through artificial intelligence. It adds up to a compelling growth story -- if you can tolerate some possible volatility, given challenging near-term end markets. A bright light in a cloudy industry Daniel Foelber (First Solar): Solar stocks soared in 2020 due to a combination of low interest rates, favorable policies, government support, and a push for clean energy. Since then, however, many solar stocks have gotten crushed as these same factors that drove the industry higher have reversed course. Borrowing costs now are elevated. And last week, the Senate Finance Committee proposed accelerating the reduction and removal of tax credits for solar and wind energy. Solar-panel manufacturer First Solar plunged on the news in lockstep with the broader industry. But even when factoring in the sell-off, First Solar has been a standout and is actually outperforming the S&P 500 over the last five years. In contrast, the solar industry, as measured by the Invesco Solar ETF, is down over that period. FSLR data by YCharts. There are several reasons why First Solar has held its own despite immense industry pressure. For starters, it's profitable and has an impeccable balance sheet. It also doesn't manufacture in China -- an advantage if trade tensions mount. The company has been expanding its U.S. footprint recently, including opening a $1.1 billion manufacturing facility in Alabama last year. These moves could pay off over the long run if government incentives and trade policy continue to favor companies that onshore their manufacturing and create U.S. jobs. Despite these advantages, First Solar still relies on government subsidies and sustained commercial investment in solar. In its Q1 2025 earnings release, First Solar guided for $1.45 billion to $2 billion in operating income. But that figure assumes $1.65 billion to $1.7 billion in 45X tax credits. The 45X tax credit incentivizes domestic production and sale of renewable energy components (like solar panels). Take away the tax credits, and First Solar's profitability and high cash flow are put in jeopardy. Given the industrywide uncertainty, it's understandable investors may be on the sidelines with First Solar stock. But the company has what it takes to ride out the industrywide downturn. Despite profitability pressures, First Solar still expects to finish 2025 with $400 million to $900 million in net cash (cash, cash equivalents, restricted cash, restricted cash equivalents, and marketable securities, less expected debt). The company also has a massive order backlog that supports years of future cash flow (although that backlog could decrease if customers pull back on purchases). Add it all up, and First Solar stands out as one of the best all-around buys in the industry for patient investors. Should you invest $1,000 in Archer Aviation right now? Before you buy stock in Archer Aviation, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Archer Aviation wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor 's total average return is994% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 23, 2025
Globe and Mail
15 minutes ago
- Globe and Mail
Is Nvidia Stock a Buy?
Nvidia (NASDAQ: NVDA) stock seems to have shrugged off its doubters. After struggling earlier this year amid a generalized sell-off and fears of lower-cost competition, the stock is on the verge of returning to its all-time high. That may have new investors wondering whether they should buy the semiconductor stock. Is there still an opportunity to earn market-beating returns from Nvidia, or have investors who didn't get in earlier missed the boat? What investors should know about Nvidia Nvidia undoubtedly benefits from its lead in the AI accelerator market. Once known primarily as a maker of graphics processing units (GPUs) for gaming, it leveraged its cutting-edge parallel processor technology to springboard into the data center and AI markets. That led to the development of the accelerators that allowed developers to bring generative AI to fruition. Consequently, 89% of its revenue in its fiscal 2026 first quarter (which ended April 27) came from its data center segment, which designs and sells its market-leading AI accelerators. That was a remarkable shift, considering that the data center segment barely exceeded the revenue levels of the gaming segment three years ago. Its success also set off alarm bells across the semiconductor industry, and competitors such as Advanced Micro Devices scrambled to catch up ever since. Even as peers work to close the gap, Nvidia continues to advance its chips. Its current top-of-the-line accelerators, such as the GPUs based on its Blackwell architecture, have enabled it to maintain its market dominance. Moreover, only Nvidia's chips can be programmed using its popular CUDA software ecosystem. That makes it more difficult for Nvidia's established customers to switch to competitors' hardware. Additionally, even though it appears that developers are finding ways to train generative AI models using lower-cost chips, demand for Nvidia's most advanced accelerators remains strong. Grand View Research forecasts a compound annual growth rate (CAGR) for the AI accelerator market of 29% through 2033. When it comes to the AI inference market, that CAGR rises above 80%, according to AMD. Thus, even if competitors can establish footholds in certain niches of this market, industry growth makes it unlikely Nvidia's peers will challenge its dominance. Nvidia's financials and what they might tell us Nvidia's financials reflect the industry's rapid expansion. In the first quarter of its fiscal 2026, revenue grew 69% year over year to $44 billion. While that was slower than its triple-digit percentage revenue growth in the previous fiscal year, the increase was unprecedented considering its $3.5 trillion market cap. Still, a 211% increase in the cost of revenue slowed earnings growth. Though it still earned nearly $19 billion in net income, the rising cost of revenue took yearly profit growth to 26%. For fiscal Q2, Nvidia expects revenue of approximately $45 billion, which would amount to a yearly increase of 50%. That estimate also accounts for an $8 billion revenue loss caused by export control limitations. Investors should also remember that the stock price has risen by an astounding 1,450% over the last five years. Yet in the past 12 months, Nvidia stock is up by only 7%. Worries about low-cost competition and tariffs weighed on the company in the first half of the year, though the stock is approaching the record high it set in January. Confusion about how to value Nvidia may also be a factor in its stock price behavior. Its P/E ratio of 47 may appear inexpensive considering the company's still-massive revenue growth and its dominance in the AI accelerator niche. Still, its price-to-sales (P/S) ratio of 24 is high enough to lead to some concerns about whether its valuation truly is compelling. Is Nvidia stock a buy? Despite those questions about the stock's valuation, Nvidia is likely to beat the market over the long term. Admittedly, competition in the AI accelerator market will probably continue to intensify. Nonetheless, the high anticipated compound annual growth rate for AI accelerators is a bullish indicator for Nvidia, and it remains the most essential company in that space by just about any standard. Thus, even if growth rates slow, they are likely to remain high enough that Nvidia's stock price growth will outpace the S&P 500 for some time to come. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor 's total average return is994% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 23, 2025
Globe and Mail
15 minutes ago
- Globe and Mail
5 AI Stocks Every Investor Should Own
Artificial intelligence (AI) isn't a bubble. It's the technological innovation of our age -- one that will alter the course of humanity for the foreseeable future. Want definitive proof? Meta Platforms (NASDAQ: META) CEO Mark Zuckerberg is reportedly willing to pay $100 million in bonus packages to poach top AI talent from rivals, personally sending WhatsApp messages to hundreds of researchers and hosting them at his homes to close deals. When one of the world's richest CEOs abandons his executive suite to become his company's chief recruiter, you know you're witnessing something far more substantial than dot-com era vaporware. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » While everyone obsesses over which company will build the first superintelligence, the smartest money is quietly accumulating positions in the companies that will profit regardless of which company wins. Think of it this way: During the California Gold Rush, the prospectors went bust -- but the folks selling picks and shovels got rich. Today's AI revolution follows the same playbook. The following five stocks are perfectly positioned to profit from every dollar spent in this technological arms race. Nvidia's hidden robotics revolution Nvidia (NASDAQ: NVDA) gets all the AI chip headlines, but the real story is its transformation into a full-stack AI computing company. While investors fixate on quarterly graphics processing unit (GPU) sales, Nvidia is quietly building the computing platform for the next generation of humanoid robots, agentic AI systems, and autonomous vehicles. The company's chips and software are becoming the preferred choice for developers building everything from factory robots to self-driving cars. The robotics market alone could reach $375 billion by 2035, yet Wall Street still values Nvidia like a semiconductor company selling commodity chips. Amazon's margin-expansion story Amazon (NASDAQ: AMZN) is deploying 750,000 robots across its fulfillment centers, but that's just the beginning of its automation journey. Its next-generation AI-powered robots are designed to work alongside human employees, handling the most physically demanding tasks while freeing workers to focus on higher-value activities. This human-robot collaboration could drive fulfillment costs down by 50% within five years through increased efficiency and reduced workplace injuries. If Amazon's automation investments pay off as expected, its operating margins could expand from today's 11.8% toward Apple -like levels above 31% -- a margin-expansion story the market hasn't begun to price in. A multitrillion-dollar digital opportunity Meta Platforms might be spending billions on AI talent, but the real payoff comes when it merges artificial intelligence with its metaverse ambitions. Imagine AI agents that can build entire virtual worlds on command, create photorealistic avatars indistinguishable from humans, and enable real-time translation across 100 languages in virtual meetings. While predicting exact market sizes is challenging, some analysts believe the AI-powered metaverse could become a multitrillion-dollar opportunity by 2035 -- a massive market hiding in plain sight. A virtual monopoly ASML (NASDAQ: ASML) owns the most important monopoly nobody talks about. This Dutch company manufactures the only extreme ultraviolet lithography machines capable of etching the nanoscale transistors required for next-generation AI chips. Every single advanced AI chip -- whether made by Nvidia, AMD, or Intel -- depends on ASML's machines. With a 10-year technological lead and a multibillion euro backlog, ASML essentially holds the keys to the entire AI hardware kingdom. A hidden AI innovator S&P Global (NYSE: SPGI) isn't building AI -- it's feeding the beast. The company's vast troves of financial data are becoming the training ground for Wall Street's AI revolution, with its new Microsoft Copilot integration putting 160 years of market intelligence at traders' fingertips. As every hedge fund and investment bank races to build AI-powered trading systems, S&P Global gets paid regardless of who wins, collecting tolls on the data superhighway that makes it all possible. The big picture The AI gold rush is real, but the smartest investors know that owning the infrastructure beats betting on individual prospectors every time. These five stocks offer diversified exposure to every corner of the AI revolution -- from the chips that power it to the data that fuels it to the platforms that will commercialize it. While some chase the latest AI start-up unicorn, investors who own these infrastructure plays -- either directly or through technology-focused exchange-traded funds (ETFs) like the Vanguard Information Technology ETF (VGT) -- are positioned to profit from the companies that make the entire ecosystem possible. The beauty of this approach? You don't need to pick which AI model wins or which start-up gets acquired. You just need exposure to the companies selling the picks and shovels to everyone digging for gold. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor 's total average return is994% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 23, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. George Budwell has positions in Apple, Microsoft, Nvidia, and Vanguard Information Technology ETF. The Motley Fool has positions in and recommends ASML, Advanced Micro Devices, Amazon, Apple, Intel, Meta Platforms, Microsoft, Nvidia, and S&P Global. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft, short August 2025 $24 calls on Intel, and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
